Long-term glycemic variability and risk of adverse outcomes: A systematic review and meta-analysis

Diabetes Care

Volumn 38, Issue 12, 2015, Pages 2354-2369

  Gorst, Catherine ^a   Kwok, Chun Shing ^b,c   Aslam, Saadia ^d   Buchan, Iain ^e   Kontopantelis, Evangelos ^a   Myint, Phyo K ^f   Heatlie, Grant ^b   Loke, Yoon ^g   Rutter, Martin K ^e,h   Mamas, Mamas A ^b,c,e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^c KEELE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

^g UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^h MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; ASIA; AUSTRALIA AND NEW ZEALAND; DIABETIC RETINOPATHY; DISEASE DURATION; EUROPE; GLYCEMIC CONTROL; GLYCEMIC VARIABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MEDICAL PARAMETERS; META ANALYSIS; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORTH AMERICA; OUTCOME ASSESSMENT; QUALITY CONTROL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ANALYSIS; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; DIABETIC ANGIOPATHY; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; RISK FACTORS;

EID: 84957981337     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1188     Document Type: Article

References (54)

1. UK Prospective Diabetes Study (UKPDDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
4. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
5. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44:968-983.
6. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008;31:2198-2202.
7. Brownlee M, Hirsch IB. Glycemic variability: A hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707-1708.
8. Cavalot F. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. Diabetes Obes Metab 2013; 15(Suppl. 2):3-8.
9. Cheng D, Fei Y, Liu Y, et al. HbA1C variability and the risk of renal status progression in diabetes mellitus: A meta-analysis. PLoS One 2014; 9:e115509.
10. Wadén J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH; Finnish Diabetic Nephropathy Study Group. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 2009;58:2649-2655.
11. Hietala K, Wadén J, Forsblom C, et al.; FinnDiane Study Group. HbA1c variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes. Diabetologia 2013;56:737-745.
12. Luk AO, Ma RC, Lau ES, et al. Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: Prospective analysis of the Hong Kong Diabetes Registry. Diabetes Metab Res Rev 2013;29:384-390.
13. Takao T, Matsuyama Y, Yanagisawa H, Kikuchi M, Kawazu S. Association between HbA1c variability and mortality in patients with type 2 diabetes. J Diabetes Complications 2014;28:494-499.
14. Hermann JM, Hammes HP, Rami-Merhar B, et al.; DPV Initiative the German BMBF Competence Network Diabetes Mellitus. HbA1c variability as an independent risk factor for diabetic retinopathy in type 1 diabetes: A German/Austrian multicenter analysis on 35, 891 patients. PLoS One 2014;9:e91137.
15. Ma WY, Li HY, Pei D, et al. Variability in hemoglobin A1c predicts all-cause mortality in patients with type 2 diabetes. J Diabetes Complications 2012;26:296-300.
16. Penno G, Solini A, Bonora E, et al.; Renal Insufficiency and Cardiovascular Events Study Group. HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Diabetes Care 2013;36: 2301-2310.
17. Penno G, Solini A, Zoppini G, et al.; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: A crosssectional analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Cardiovasc Diabetol 2013;12:98.
18. Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: The ADVANCE trial. Diabetes Care 2014;37:2359-2365.
19. Skriver MV, Sandbæk A, Kristensen JK, Støvring H. Relationship of HbA1c variability, absolute changes in HbA1c, and all-cause mortality in type 2 diabetes: A Danish populationbased prospective observational study. BMJ Open Diabetes Res Care 2015;3:e000060.
20. Foo V, Tan G, Sabanayagam C, et al. HbA1c variability and diabetic retinopathy in Asian type 2 diabetes. Invest Ophthalmol Vis Sci 2014;55:4412.
21. Smith-Palmer J, Brändle M, Trevisan R, Orsini Federici M, Liabat S, Valentine W. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Res Clin Pract 2014;105:273-284.
22. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: Evidence from a systematic review of the literature. Diabetes Obes Metab 2010;12:288-298.
23. Cummings DM, Larsen LC, Doherty L, Lea CS, Holbert D. Glycemic control patterns and kidney disease progression among primary care patients with diabetes mellitus. J Am Board Fam Med 2011;24:391-398.
24. Hsu CC, Chang HY, Huang MC, et al. HbA1c variability is associated with microalbuminuria development in type 2 diabetes: A 7-year prospective cohort study. Diabetologia 2012;55: 3163-3172.
25. Raman S, Delurgio sr SA, Lind M, Kosiborod M, Fridlington AG, et al. A1C variability predicts the risk of microalbuminuria among children with type 1 diabetes mellitus (T1DM). Presented at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, San Diego, CA.
26. Rodríguez-Segade S, Rodŕiguez J, García López JM, Casanueva FF, Camina F. Intrapersonal HbA(1c) variability and the risk of progression of nephropathy in patients with type 2 diabetes. Diabet Med 2012;29:1562-1566.
27. Sugawara A, Kawai K, Motohashi S, et al. HbA(1c) variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. Diabetologia 2012; 55:2128-2131.
28. Lin CC, Chen CC, Chen FN, et al. Risks of diabetic nephropathy with variation in hemoglobin A1c and fasting plasma glucose. Am J Med 2013;126:1017.e1-1017.e10.
29. Marcovecchio ML, Dalton RN, Chiarelli F, Dunger DB. A1C variability as an independent risk factor for microalbuminuria in young peoplewith type 1 diabetes. Diabetes Care 2011;34: 1011-1013.
30. Department of Health. National Service Framework for Diabetes. London, Department of Health, 2001.
31. Health and Social Care Information Centre. Quality and outcomes framework, 2014. Available from http://www.hscic.gov.uk/qof Accessed 27 May 2015.
32. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ 1998;316:989-991.
33. Loke YK, Price D, Herxheimer A. Adverse effects. In Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT, Green S, Eds. Chichester, U.K., Wiley, 2008.
34. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: A large survey. CMAJ 2007;176: 1091-1096.
35. Nazim J, Fendler W, Starzyk J. Metabolic control and its variability are major risk factors for microalbuminuria in children with type 1 diabetes. Endokrynol Pol 2014;65:83-89.
36. Lang C, Levin D, Mohan M, et al. Effect of glycaemic control on outcome in patients with type 2 diabetes mellitus and chronic heart failure. J Am Coll Cardiol 2015;65(Suppl. 1):A886.
37. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687.
38. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:1349-1354.
39. Chang C-M, Hsieh C-J, Huang J-C, Huang I-C. Acute and chronic fluctuations in blood glucose levels can increase oxidative stress in type 2 diabetes mellitus. Acta Diabetol 2012;49(Suppl. 1):S171-S177.
40. Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: The distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 2005;183:259-267.
41. Ceriello A, Ihnat MA. 'Glycaemic variability': A new therapeutic challenge in diabetes and the critical care setting. DiabetMed 2010;27:862-867.
42. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000;18:655-673.
43. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-790.
44. Kilpatrick ES. The rise and fall of HbA(1c) as a risk marker for diabetes complications. Diabetologia 2012;55:2089-2091.
45. Schisano B, Tripathi G, McGee K, McTernan PG, Ceriello A. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Diabetologia 2011;54:1219-1226.
46. Keating ST, El-Osta A. Glycemic memories and the epigenetic component of diabetic nephropathy. Curr Diab Rep 2013;13:574-581.
47. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-389.
48. Groop PH, Forsblom C, Thomas MC. Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 2005;1:100-110.
49. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(Suppl. 4):8-13.
50. Maciejewski ML, Dowd B, Call KT, Feldman R. Comparing mortality and time until death for Medicare HMO and FFS beneficiaries. Health Serv Res 2001;35:1245-1265.
51. Hamer M, Stamatakis E, Kivimäki M, Pascal Kengne A, Batty GD. Psychological distress, glycated hemoglobin, and mortality in adults with and without diabetes. Psychosom Med 2010;72: 882-886.
52. Kontopantelis E, Springate DA, Reeves D. A re-analysis of the Cochrane Library data: The dangers of unobserved heterogeneity in metaanalyses. Plos One 2013;8:e69930.
53. Kontopantelis E, Reeves D. Performance of statistical methods for meta-analysis when true study effects are non-normally distributed: A simulation study. Stat Methods Med Res 2012; 21:409-426.
54. Sperrin M, Thew S, Weatherall J, Dixon W, Buchan I. Quantifying the longitudinal value of healthcare record collections for pharmacoepidemiology. AMIA Annu Symp Proc 2011;2011: 1318-1325.